Neo Ivy Capital Management Has $2.99 Million Stock Position in Vaxcyte, Inc. $PCVX

Neo Ivy Capital Management increased its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 242.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 83,110 shares of the company’s stock after purchasing an additional 58,869 shares during the quarter. Neo Ivy Capital Management owned approximately 0.06% of Vaxcyte worth $2,994,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. HighVista Strategies LLC boosted its holdings in shares of Vaxcyte by 1.1% in the second quarter. HighVista Strategies LLC now owns 33,457 shares of the company’s stock worth $1,088,000 after buying an additional 355 shares during the period. Arizona State Retirement System lifted its position in shares of Vaxcyte by 1.6% in the 3rd quarter. Arizona State Retirement System now owns 34,333 shares of the company’s stock valued at $1,237,000 after acquiring an additional 543 shares in the last quarter. Atria Investments Inc boosted its stake in Vaxcyte by 11.1% in the 2nd quarter. Atria Investments Inc now owns 6,816 shares of the company’s stock worth $222,000 after purchasing an additional 683 shares during the period. Hsbc Holdings PLC grew its position in Vaxcyte by 4.1% during the 2nd quarter. Hsbc Holdings PLC now owns 19,216 shares of the company’s stock worth $628,000 after purchasing an additional 755 shares in the last quarter. Finally, Virtus Investment Advisers LLC grew its position in Vaxcyte by 45.8% during the 2nd quarter. Virtus Investment Advisers LLC now owns 2,729 shares of the company’s stock worth $89,000 after purchasing an additional 857 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on PCVX shares. Guggenheim restated a “buy” rating and issued a $116.00 target price on shares of Vaxcyte in a report on Monday, February 2nd. Leerink Partners set a $77.00 price target on Vaxcyte and gave the company an “outperform” rating in a report on Wednesday, November 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research report on Friday, January 9th. BTIG Research increased their price objective on Vaxcyte from $85.00 to $89.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Finally, Needham & Company LLC raised their price objective on Vaxcyte from $90.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $94.50.

Vaxcyte Trading Up 1.8%

Vaxcyte stock opened at $59.29 on Friday. The company has a market capitalization of $8.53 billion, a P/E ratio of -10.55 and a beta of 1.31. The firm’s fifty day simple moving average is $52.98 and its 200-day simple moving average is $44.91. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $76.61.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, February 24th. The company reported ($1.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.46) by ($0.34). During the same period in the previous year, the company posted ($1.12) EPS. On average, equities research analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Insider Activity

In other news, insider Harpreet S. Dhaliwal sold 9,743 shares of the stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $46.69, for a total transaction of $454,900.67. Following the transaction, the insider owned 23,928 shares of the company’s stock, valued at approximately $1,117,198.32. This represents a 28.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Elvia Cowan sold 11,623 shares of the firm’s stock in a transaction that occurred on Tuesday, December 23rd. The shares were sold at an average price of $47.92, for a total value of $556,974.16. Following the completion of the transaction, the senior vice president directly owned 14,534 shares in the company, valued at $696,469.28. The trade was a 44.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 3.10% of the stock is owned by company insiders.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.